Hypertension, nitric oxide and end-organ damage

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 2, 1999, Pages 237-241

  Ishani, Areef ^a   Raij, Leopoldo ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CORONARY RISK; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHEAR STRESS;

EID: 0033006794     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199903000-00014     Document Type: Review

References (56)

1. Kaplan NM. Primary hypertension: natural history. In: Clinical hypertension, 4th edn. Kaplan NM (editor) Baltimore, MD: Williams and Williams; 1986. pp. 123-146.
2. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive endstage renal disease? Arch Intern Med 1991; 151:1359-1364.
3. Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications (clinical conference). Hypertension 1994; 23:531-535.
4. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13 (Suppl.):180-193.
5. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108:1347-1352.
6. Parving HH. Microalbuminuria in essential hypertension and diabetes. J Hypertens 1996; 14 (Suppl. 2):S89-S93.
7. Gibbons GH, Dau VJ The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
8. Palmer RMJ, Fernge AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. Nature 1987; 327:524-526
9. Baylis C, Mitruka B, Deng A Chronic inhibition of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90:278-281
10. Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: an new model of arterial hypertension. Hypertension 1992; 20:298-303.
11. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 1992; 90:647-652
12. Hu L, Manning D, Brands MW. Long-term cardiovascular role of nitric oxide in conscious rats Hypertension 1994; 23:185-194.
13. Ribeiro MO, Antunes E, DeNucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis, a new model of arterial hypertension. Hypertension 1992; 20:298-281.
14. Qiu C, Engels K, Samsell L, Baylis C. Renal effects of amino acid infusion in hypertension induced by chronic nitric oxide formation in the young Wistar rat role of renin and vascular hypertrophy. J Hypertens 1993; 11:1083-1088.
15. Pollock DM, Polakowski JS, Divish BJ, Opegenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 1993; 21:660-666.
16. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy J Hypertens 1993; 11:1083-1088.
17. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
18. Griendling KK, Minien CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
19. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Gnendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996, 97:1916-1923.
20. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 1993; 18:195-199.
21. - production by the mesangial cells.
22. Rubanyi GM, Vanhoutte PM Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986; 250:H822-H827.
23. Gryglewski RI, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor Nature 1986; 320:454-456.
24. Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Watanabe M, et al. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 1995; 80:2198-2202
25. •] below.
26. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998; 32:527-533. These two studies demonstrate the effect of NO on angiotensin II receptor expression.
27. King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989; 256:1051-1058.
28. Mene P, Simonson MS, Dunn MJ. Physiology of the mesangial cell Physiol Rev 1989; 69:1347-1424.
29. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in tranagenic mice. Role of endothelin. J Clin Invest 1998; 101:2780-2789.
30. Raij L, Baylis C. Glomerular actions of nitric oxide [Editorial Review]. Kidney Int 1995; 48:20-32.
31. Peiro C, Redondo J, Rodriguez-Martinez MA, Angulo J, Mann J, Sanchez-Ferrer CF. Influence of endothelium on cultured vascular smooth muscle cell proliferation. Hypertension 1995; 25:748-751.
32. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
33. ••] below.
34. Sheasely EG, Maeda N, Kim HS, Desai KM, Krege JH, Lauback VE, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93:13176-13181.
35. ••] interesting studies demonstrate that a primary defect in endothelial NOS may promote abnormal cardiovascular remodelling.
36. Schnackenberg CG, Wilkins FC, Granger JP. Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Hypertension 1995; 26-1024-1029.
37. Su EJ, Lombardi OM, Stegal J, Schwart SM. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998; 31:1331-1337. A study showing that angiotensin II promotes vascular smooth muscle proliferation independent of blood pressure.
38. Rosendorff C Vascular hypertrophy in hypertension: role of the reninangiotensin system. Mt Sinai J Med 1998; 65:108-117. An overview of the role of the renin-angiotensin system.
39. Lundie MJ, Friberg P, Kline RL, Adams MA. Long-term inhibition of the reninangiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. J Hypertens 1997; 15.339-348 A comprehensive review regarding the effects of long-term ACE inhibition in hypertensive animals.
40. Takemoto M, Egashira K, Usui M, Namaguchi K, Tomita H, Tsutsui H, et al. Important role of tissue angiotensin-converting enzyme activity in the pathorgenesis of coronary vascular and myocardial structural changes induced by long-term blockage of nitric oxide synthesis in rats. J Clin Invest 1997; 99:278-287.
41. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998; 135(suppl 2)-S21-S30. An excellent review of the effect of ACE inhibitors on vascular remodelling.
42. Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension 1998; 31:266-270. A good study demonstrating that increased NO may protect against hypertensive end-organ damage.
43. Vallance P, Collier J, Moncada S. Effect of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989, 2:997-1000
44. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelial-dependent relaxation in patients with essential hypertension N Engl J Med 1990; 323:22-27.
45. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo Circulation 1990; 81:1762-1767.
46. Panza JA, Casino PR, Kilcyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. Circulation 1993; 87:1468-1474.
47. Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, Takeshida A Captopril improves impaired endothelium-dependent vasodilatation in hypertensive patients. Hypertension 1992; 20:175-180.
48. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10:1025-1031.
49. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilatation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21:929-933.
50. Cardillo C, Kilcoyne CM, Cannon III RO, Panza JA. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circuiation. Hypertension 1998; 31:1235-1239
51. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginmenitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94:1298-1303.
52. Cardillo C, Kilcoyne CM, Quyyumi AA, Canonon III RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilatation in patients with essential hypertension. Circulation 1998; 97:851-856. A study suggesting that endothelial dysfunction in hypertension may be secondary to a signaling defect.
53. Guyton AC, Coleman TG, Cowley Jr AW, Scheel KW, Manning Jr RD, Norman Jr RA. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation in hypertension. Am J Med 1972; 52:484-594.
54. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997; 29:235-241.
55. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991, 88:1559-1567.
56. Miyoshi A, Suzuki H, Fujiwara M, Masai M, Iwasaki T. Impairment of endothelial function in salt-sensitive hypertension in humans. Am J Hypertens 1997;10:1083-1090.